NASDAQ$BNGO

BioNano Genomics Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Bionano Genomics reported Q4 2024 revenue of $8.2M, a net loss of $20.1M.

For Q4 2024, Bionano Genomics reported Revenue was $8.2M, net loss was $20.1M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Revenue $8.2M for Q4 2024.
  • Net loss $20.1M.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$8.2M

Previous: $10.7M-23.5%
EPS (adj)

$0.00

Previous: -$0.96+100.0%
Flowcells Sold

8.1K

Previous: 8.0K+1.0%
OGM Installed Base

371

Previous: 326+13.8%
GAAP Gross Margin

42.0%

Previous: 23.0%+82.6%
Non-GAAP Gross Margin

42.0%

Previous: 24.0%+75.0%
GAAP Operating Expense

$15.4M

Previous: $27.4M-43.9%
Non-GAAP Operating Expense

$10.6M

Previous: $26.6M-60.0%
OGM Publications

82

Previous: 92-10.9%
Net Income

-$20.1M

Previous: -$43.9M+54.1%
Operating Income

-$11.9M

Previous: -$25M+52.1%
Gross Profit

$3.42M

Previous: $2.44M+40.2%

Revenue & EPS history

BioNano · Revenue · Quarterly

$8.2M

Q4 2024-23.5%vs Q4 2023
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

BioNano · $9.32M total across 2 segments · Q3 2023

  • Product Revenue
    $6.46M+79.0%
  • Service and Other Revenue
    $2.86M-20.8%

Forward guidance

Outlook emphasizes milestones, liquidity runway, and cost discipline.

Tailwinds

  • Pipeline progress and partnership economics.
  • Cash supports near-term operating plans.

Headwinds

  • Operating losses until commercial scale.
  • Financing and competition affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-3.3%

Avg return

Earnings day

-5.4%

Avg return

5 days after

-7.7%

Avg return

30 days after

40%

12 / 30 earnings

Positive

+15.5%

Q4 2018

Best reaction

-29.8%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+0.9%+1.6%
Q1 2026-0.8%-9.5%-7.9%
Q3 2025+2.8%+4.8%+10.2%
Q1 2025+2.9%+0.8%-2.4%
Q4 2024+11.1%+8.6%+43.4%
Q3 2024-3.4%-11.5%-7.7%
Q2 2024-21.5%-23.5%-13.7%
Q1 2024+2.7%+7.3%-9.4%
Q4 2023+0.0%-5.8%-18.2%
Q3 2023-7.0%-10.5%+2.8%
Q2 2023-0.2%-13.9%-15.7%
Q1 2023+6.9%-9.6%+0.0%
Q4 2022-8.4%-5.3%-19.8%
Q3 2022+2.7%+2.2%-6.3%
Q2 2022+6.6%+0.0%+2.2%
Q1 2022-16.1%-24.2%-10.8%
Q4 2021+1.4%-10.7%+20.6%
Q3 2021-9.8%-13.7%-44.4%
Q2 2021+5.4%+4.4%-1.0%
Q1 2021+13.9%+22.8%+59.9%
Q4 2020-17.9%-14.4%-34.1%
Q3 2020-7.4%-5.4%-10.7%
Q2 2020-8.4%-6.5%-32.5%
Q1 2020-8.4%-11.8%+21.6%
Q4 2019-29.8%-30.3%-74.3%
Q3 2019-2.1%+17.8%+24.4%
Q2 2019-14.4%-11.3%-50.5%
Q1 2019-11.3%-17.0%-28.1%
Q4 2018+15.5%+7.4%-8.1%
Q3 2018-6.0%-5.7%-11.9%
Q2 2018
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro